AR089425A1 - Anticuerpo ctgf (factor de crecimiento de tejido conectivo) antihumano - Google Patents
Anticuerpo ctgf (factor de crecimiento de tejido conectivo) antihumanoInfo
- Publication number
- AR089425A1 AR089425A1 ARP120104933A ARP120104933A AR089425A1 AR 089425 A1 AR089425 A1 AR 089425A1 AR P120104933 A ARP120104933 A AR P120104933A AR P120104933 A ARP120104933 A AR P120104933A AR 089425 A1 AR089425 A1 AR 089425A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- human ctgf
- growth factor
- antihuman
- connective tissue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011281811 | 2011-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089425A1 true AR089425A1 (es) | 2014-08-20 |
Family
ID=48668601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104933A AR089425A1 (es) | 2011-12-22 | 2012-12-21 | Anticuerpo ctgf (factor de crecimiento de tejido conectivo) antihumano |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9587015B2 (enExample) |
| EP (1) | EP2796550B1 (enExample) |
| JP (1) | JP6040943B2 (enExample) |
| KR (1) | KR20140107507A (enExample) |
| CN (1) | CN104011206B (enExample) |
| AR (1) | AR089425A1 (enExample) |
| BR (1) | BR112014015405A2 (enExample) |
| CA (1) | CA2859627A1 (enExample) |
| EA (1) | EA029290B1 (enExample) |
| ES (1) | ES2665851T3 (enExample) |
| IN (1) | IN2014CN04615A (enExample) |
| MX (1) | MX345019B (enExample) |
| PL (1) | PL2796550T3 (enExample) |
| PT (1) | PT2796550T (enExample) |
| TW (1) | TW201333034A (enExample) |
| WO (1) | WO2013094723A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824777A (zh) * | 2019-03-15 | 2019-05-31 | 辽宁何氏医学院 | 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| CA3142092A1 (en) * | 2019-06-04 | 2020-12-10 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-connective tissue growth factor antibody and application thereof |
| US20230416352A1 (en) * | 2020-12-03 | 2023-12-28 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-connective tissue growth factor antibody |
| JPWO2023238845A1 (enExample) | 2022-06-07 | 2023-12-14 | ||
| AU2023373601A1 (en) | 2022-10-31 | 2025-04-03 | Astellas Pharma Inc. | Antibody-drug conjugate containing a toll-like receptor 7/8 dual agonist compound |
| WO2024188179A1 (zh) * | 2023-03-10 | 2024-09-19 | 上海济煜医药科技有限公司 | 一种靶向ctgf的抗体或其抗原结合片段及其应用 |
| WO2025047848A1 (ja) | 2023-08-30 | 2025-03-06 | アステラス製薬株式会社 | ＩｄｅＺ改変体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| DE69433422T2 (de) | 1993-03-11 | 2004-09-16 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Monoklonaler anti-hiv antikörper |
| JP4537507B2 (ja) | 1997-12-25 | 2010-09-01 | アムジェン インコーポレイテッド | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
| US6562618B1 (en) | 1997-12-25 | 2003-05-13 | Japan Tobacco, Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| MXPA01005949A (es) | 1998-12-14 | 2002-09-18 | Univ Miami | Fragmentos de factor de crecimiento de tejido conectivo y metodos y usos de los mismos. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
-
2012
- 2012-12-21 JP JP2013550349A patent/JP6040943B2/ja not_active Expired - Fee Related
- 2012-12-21 CA CA2859627A patent/CA2859627A1/en not_active Abandoned
- 2012-12-21 US US14/367,081 patent/US9587015B2/en not_active Expired - Fee Related
- 2012-12-21 WO PCT/JP2012/083206 patent/WO2013094723A1/ja not_active Ceased
- 2012-12-21 BR BR112014015405A patent/BR112014015405A2/pt unknown
- 2012-12-21 AR ARP120104933A patent/AR089425A1/es unknown
- 2012-12-21 MX MX2014007681A patent/MX345019B/es active IP Right Grant
- 2012-12-21 TW TW101148989A patent/TW201333034A/zh unknown
- 2012-12-21 PT PT128607421T patent/PT2796550T/pt unknown
- 2012-12-21 ES ES12860742.1T patent/ES2665851T3/es active Active
- 2012-12-21 PL PL12860742T patent/PL2796550T3/pl unknown
- 2012-12-21 KR KR1020147020039A patent/KR20140107507A/ko not_active Abandoned
- 2012-12-21 IN IN4615CHN2014 patent/IN2014CN04615A/en unknown
- 2012-12-21 EP EP12860742.1A patent/EP2796550B1/en active Active
- 2012-12-21 EA EA201491240A patent/EA029290B1/ru not_active IP Right Cessation
- 2012-12-21 CN CN201280063995.5A patent/CN104011206B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL2796550T3 (pl) | 2018-08-31 |
| CN104011206B (zh) | 2017-03-08 |
| MX2014007681A (es) | 2014-11-25 |
| EA201491240A1 (ru) | 2014-11-28 |
| JP6040943B2 (ja) | 2016-12-07 |
| BR112014015405A2 (pt) | 2017-06-13 |
| EP2796550A4 (en) | 2015-08-19 |
| WO2013094723A1 (ja) | 2013-06-27 |
| TW201333034A (zh) | 2013-08-16 |
| MX345019B (es) | 2017-01-11 |
| JPWO2013094723A1 (ja) | 2015-04-27 |
| EA029290B1 (ru) | 2018-03-30 |
| US9587015B2 (en) | 2017-03-07 |
| EP2796550B1 (en) | 2018-02-28 |
| CN104011206A (zh) | 2014-08-27 |
| PT2796550T (pt) | 2018-04-18 |
| IN2014CN04615A (enExample) | 2015-09-18 |
| KR20140107507A (ko) | 2014-09-04 |
| ES2665851T3 (es) | 2018-04-27 |
| US20140343258A1 (en) | 2014-11-20 |
| EP2796550A1 (en) | 2014-10-29 |
| CA2859627A1 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087608A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
| AR117658A2 (es) | Anticuerpos anti-fap y métodos de uso | |
| AR098950A1 (es) | Anticuerpo contra bdca-2 humano | |
| AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
| MX2015008920A (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t. | |
| PE20141166A1 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| EA201491700A1 (ru) | Человеческие антитела к cd27, методы и применение | |
| EA201490433A1 (ru) | Новое антитело против ngf человека | |
| AR106201A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| CL2014000134A1 (es) | Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina. | |
| EA201391312A1 (ru) | Антитело к человеческому тканевому фактору и его применение | |
| PE20121702A1 (es) | Proteinas de enlace cd127 | |
| EA201490546A1 (ru) | Замещенные аннелированные пиримидины и их применение | |
| EA201400709A1 (ru) | Молекула биспецифического антитела | |
| EA201300137A1 (ru) | Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями | |
| PE20141028A1 (es) | Nuevos moduladores y metodos para su uso | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| EA201790757A1 (ru) | Связывающие антиген cd27l белки | |
| BR112012021329A2 (pt) | anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo. | |
| AR082149A1 (es) | Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso | |
| EA201491235A1 (ru) | Варианты полипептидов fc-pol с улучшенным связыванием неонатального рецептора fc | |
| EA201491240A1 (ru) | Новое антитело против ctgf человека | |
| EA201492163A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ | |
| AR073978A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |